Results 61 to 70 of about 15,859 (208)

A Case of Adjuvant Brigatinib in a Patient with ALK-rearranged R0 Resected Oligometastatic Lung Cancer [PDF]

open access: yes
Anaplastic lymphoma kinase (ALK) rearrangement is detected at a low rate in non-small cell lung cancer (NSCLC). Patients with ALK rearrangements have poor responses to conventional cytotoxic chemotherapy.
Nalan Akyürek   +4 more
core   +1 more source

Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

open access: yes, 2022
20.500.12530/87854Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC).
Fernando López-Campos   +23 more
core   +1 more source

Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Prophylactic pelvic nodal radiotherapy (PRT) aims to eradicate occult pelvic nodal disease in oligometastatic prostate cancer but increases lymphocyte exposure. Its early hematologic safety and lymphocyte recovery when added to radiotherapy to the prostate/prostate region and all imaging‐visible metastases remain uncertain.
Xin Qi   +13 more
wiley   +1 more source

Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer

open access: yesRadiation Oncology, 2021
Background The aim of this work was to investigate the outcome of metastasis-directed radiotherapy (MDT) in prostate cancer patients with bone metastases following current ESTRO/EORTC subclassifications for oligometastatic disease.
Paul Rogowski   +10 more
doaj   +1 more source

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC

open access: yesCurrent Oncology, 2021
Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti ...
Camille Gauvin   +11 more
doaj   +1 more source

Steering decision making by terminology : oligometastatic versus argometastatic

open access: yes, 2022
: Allowing selected patients with few distant metastases to undergo potentially curative local ablation, the designation "oligometastatic" has become a widely popular concept in oncology.
Szturz, P.   +5 more
core   +1 more source

Multifocal Gastrointestinal Melanoma Metastases More Than Two Decades After Primary Diagnosis: Complete Resection and Long‐Term Follow‐Up

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Melanoma may present with gastrointestinal metastases decades after primary diagnosis. A man treated for cutaneous melanoma in 1992 had local recurrence in 1993 and an in‐transit metastasis in 2013. Intestinal metastases were resected in 2017. No further recurrence was documented through June 2026.
Per Nyman   +4 more
wiley   +1 more source

Stereotactic radiotherapy in oligometastatic cancer

open access: yesChinese Clinical Oncology, 2017
Oligometastatic cancer describes a disease state somewhere between localized and metastatic cancer. Proposed definitions of oligometastatic disease have typically used a cut-off of five or fewer sites of disease. Treatment of oligometastatic disease should have the goal of long-term local control, and in selected cases, disease remission. While several
Thomas A C, Kennedy   +2 more
openaire   +2 more sources

Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer

open access: yes, 2021
Oligometastatic cancer is characterized by a limited number of metastatic deposits. Compared with lung cancer patients who have more widespread disease, oligometastatic lung cancer patients have more favorable survival outcomes.
David L. Billing, Andreas Rimner
core   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

open access: yesInternational Journal of Cancer, Volume 159, Issue 9, Page 2244-2261, 1 November 2026.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy